Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice | Zendy

Hjalmar Wadström | Zendy; Thomas Frisell | Zendy; Johan Askling | Zendy

Open Access

Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice

Author(s) -

Hjalmar Wadström,

Thomas Frisell,

Johan Askling

Publication year - 2017

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2017.4332

Subject(s) - medicine , abatacept , tocilizumab , rheumatoid arthritis , rituximab , hazard ratio , cohort , population , tnf inhibitor , oncology , adalimumab , lymphoma , confidence interval , environmental health

Considering the widespread and increasing use of biological immunomodulators (biological disease-modifying antirheumatic drugs [bDMARDs]) to treat chronic inflammatory conditions, and the concern that immunomodulation may alter cancer risk and progression, the limited available data on use of these therapies as used in clinical practice and cancer risks are a concern.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research